BioSafe, BIO’s nonclinical safety committee, outlines challenges and offers opportunities for developing redosable gene therapies. Read more on

The Rare Pediatric Disease Priority Review Voucher (RPD PRV) fuels innovation across the U.S., enabling researchers to deliver lifesaving treatments for children. Patient advocates and biotech leaders are urging for its immediate reauthorization.

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

#TheNextFrontier, produced by @BBCStoryWorks for BIO, shares BIO President & CEO John F. Crowley’s personal journey and how it fuels BIO’s mission to strengthen #biotech’s innovation leadership and spark hope for millions of patients.

The U.S. Small Business Innovation Research (#SBIR) funding has remained a lifeline for small-medium sized #biotech innovators fighting to bring their treatments to patients for 40+ years. Without action, the program will expire Sept. 30. More:

The FDA has accelerated the approval of a new targeted glioma treatment, marking a milestone for Jazz Pharmaceuticals - and for U.S. biotech competitiveness. It’s a massive breakthrough for families facing this rare, aggressive brain cancer and underscores the power of innovation.

Kristin's story underscores why Congress must reauthorize the Rare Pediatric #PRVprogram - an essential driver of critical treatments for kids with rare diseases.

Kicking off Children’s Eye Health and Safety Month, spoke with mother, award winning author, and Co-founder and CEO of @KristinSmedley about her mission to cure CRB1. Read more:

The Rare Pediatric Disease Priority Review Voucher (RPD PRV) program has brought forward 53 new treatments across 39 rare pediatric diseases. Without its immediate reauthorization, this momentum – and millions of young lives – are at risk.

BIO’s advocacy on the Hill welcomed special guests last week. Members of BIO’s Executive Committee met with congressional leaders on critical #biotech issues - from immediate reauthorization of the PPRV program to increasing supply chain resilience and the implications of

#BIOontheAmericanRoad's recent stop in Virginia fostered—and captured—inspiring conversation between our incredible state partners, including John Newby, CEO of @vabio; Chris Rogers, Chief Commercial Officer of @PhlowUSA; and Amy Yarcich, Executive Director of @RxPartnershipVA.

Against the broad spectrum of technology sectors, biomanufacturers face many hurdles in protecting and attaining patents critical for broadening treatment application and patient accessibility. BIO's Dr. Hans Sauer explains:

Biotech leaders: Strong intellectual property (IP) protections are essential to sustaining U.S. innovation leadership and ensuring expanded patient access to lifesaving treatments. Read more:

Yesterday, EC members took to Capitol Hill to meet w/ congressional leaders on key #biotech policy priorities - from strengthening #IP protections and #supplychain resilience to immediate reauthorization of the PRV program and the implications of tariffs on #biotech innovation.

We're excited to welcome the BIO Executive Committee to Washington for two days of advocacy-packed conversations.

.@Alnylam CEO @ygreenst underscores the urgency for congressional action on the #MINIAct to support small #biotech companies advancing #GeneticallyTargetedTechnologies. Fixing the #IRA’s treatment of GTT is key to protecting future breakthroughs:

The Rare Pediatric Disease PRV program has expired and without immediate reauthorization, the pipeline for lifesaving pediatric rare disease treatments will stall. Patients can’t wait. Learn more:

Last week, BIO President & CEO John F. Crowley visited Virginia as part of #BIOontheAmericanRoad, highlighting the state’s booming #biotech ecosystem. Since 2022, Virginia has invested $1B+ in R&D, creating 400+ new patents and driving innovation forward.

“BIO is at the epicenter of coming up with groundbreaking policy solutions that actually can change the healthcare paradigm in the U.S.” BIO sat down with our new board chair, Fritz Bittenbender.

Fully vaccinating individuals saves an estimated $4,637 in medical costs per person. Learn more about the critical role immunization plays in protecting our communities and economy: #WhyWeVaccinate

#BIOontheAmericanRoad is in Virginia! BIO President and CEO John F. Crowley, alongside @vabio, toured @PhlowUSA's state-of-the-art pharmaceutical manufacturing facility in Petersburg, focused on improving the resiliency of American pharmaceutical supply chains + development.